Macquarie Group’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$44.2M Buy
703,043
+622,459
+772% +$43.3M 0.26% 76
2025
Q4
$5.35M Sell
80,584
-60,518
-43% -$3.91M 0.02% 388
2025
Q3
$9.49M Buy
141,102
+6,430
+5% +$509K 0.01% 825
2025
Q2
$11.8M Buy
134,672
+27,342
+25% +$2.14M 0.01% 782
2025
Q1
$7.33M Buy
107,330
+10,757
+11% +$878K 0.01% 880
2024
Q4
$6.33M Sell
96,573
-1,439,719
-94% -$107M 0.01% 900
2024
Q3
$103M Sell
1,536,292
-502,679
-25% -$41.3M 0.11% 258
2024
Q2
$231M Sell
2,038,971
-177,711
-8% -$22.5M 0.27% 80
2024
Q1
$307M Sell
2,216,682
-576,189
-21% -$72.4M 0.35% 56
2023
Q4
$347M Sell
2,792,871
-240,608
-8% -$24.6M 0.4% 42
2023
Q3
$283M Sell
3,033,479
-84,531
-3% -$9.53M 0.36% 53
2023
Q2
$401M Sell
3,118,010
-181,857
-6% -$22M 0.46% 46
2023
Q1
$383M Sell
3,299,867
-163,524
-5% -$18.3M 0.46% 45
2022
Q4
$392M Sell
3,463,391
-192,010
-5% -$21.1M 0.46% 42
2022
Q3
$294M Buy
3,655,401
+373,898
+11% +$31.7M 0.36% 49
2022
Q2
$245M Sell
3,281,503
-1,061,601
-24% -$96.9M 0.27% 67
2022
Q1
$555K Sell
4,343,104
-159,012
-4% -$17.4M 0.42% 39
2021
Q4
$604M Buy
4,502,116
+954,156
+27% +$137M 0.5% 31
2021
Q3
$485M Sell
3,547,960
-252,004
-7% -$31.8M 0.41% 52
2021
Q2
$406M Buy
3,799,964
+3,606,836
+1,868% +$346M 0.33% 64
2021
Q1
$17.4M Sell
193,128
-6,220
-3% -$584K 0.02% 570
2020
Q4
$18.4M Buy
199,348
+24,900
+14% +$2.22M 0.03% 545
2020
Q3
$18M Sell
174,448
-8,376
-5% -$875K 0.03% 501
2020
Q2
$18.5M Sell
182,824
-439,860
-71% -$39.3M 0.03% 479
2020
Q1
$41.9M Buy
622,684
+110,296
+22% +$6.86M 0.09% 248
2019
Q4
$28M Sell
512,388
-214,308
-29% -$10.2M 0.04% 423
2019
Q3
$27.1M Sell
726,696
-15,080
-2% -$586K 0.05% 389
2019
Q2
$27.8M Buy
741,776
+42,468
+6% +$1.33M 0.05% 382
2019
Q1
$20.8M Sell
699,308
-34,184
-5% -$1.2M 0.04% 453
2018
Q4
$22M Sell
733,492
-51,500
-7% -$1.63M 0.04% 401
2018
Q3
$28.1M Sell
784,992
-160,372
-17% -$4.97M 0.05% 398
2018
Q2
$22.4M Buy
945,364
+119,300
+14% +$2.53M 0.04% 451
2018
Q1
$15.3M Buy
826,064
+73,356
+10% +$1.08M 0.03% 526
2017
Q4
$10.8M Sell
752,708
-164,216
-18% -$2.13M 0.02% 617
2017
Q3
$11.2M Sell
916,924
-53,468
-6% -$945K 0.02% 585
2017
Q2
$17.7M Buy
970,392
+389,916
+67% +$7.2M 0.03% 475
2017
Q1
$12.3M Sell
580,476
-64,984
-10% -$1.27M 0.02% 567
2016
Q4
$9.63M Sell
645,460
-149,824
-19% -$2.65M 0.02% 613
2016
Q3
$17.4M Sell
795,284
-975,436
-55% -$21.7M 0.03% 464
2016
Q2
$35.1M Buy
1,770,720
+1,218,100
+220% +$20.7M 0.03% 414
2016
Q1
$9.38M Buy
552,620
+261,068
+90% +$4.36M 0.02% 571
2015
Q4
$5.97M Buy
291,552
+174,120
+148% +$3.62M 0.01% 665
2015
Q3
$2.52M Sell
117,432
-507,100
-81% -$11.3M 0.01% 912
2015
Q2
$12.5M Sell
624,532
-540,828
-46% -$9.5M 0.02% 469
2015
Q1
$18.2M Buy
1,165,360
+82,964
+8% +$1.25M 0.04% 397
2014
Q4
$14.9M Buy
1,082,396
+160,512
+17% +$1.97M 0.03% 436
2014
Q3
$9.22M Buy
921,884
+161,232
+21% +$1.65M 0.02% 528
2014
Q2
$7.54M Buy
760,652
+503,484
+196% +$4.46M 0.02% 588
2014
Q1
$2.66M Sell
257,168
-27,552
-10% -$285K ﹤0.01% 911
2013
Q4
$2.52M Buy
284,720
+38,164
+15% +$302K ﹤0.01% 904
2013
Q3
$1.74M Buy
246,556
+42,116
+21% +$267K ﹤0.01% 998
2013
Q2
$1.15M Buy
+204,440
New +$979K ﹤0.01% 1121

Other funds holding DXCM

Macquarie Group's DXCM Position: Q1 2026 in Review

Macquarie Group increased its DexCom (DXCM) stake by 772% in Q1 2026, buying an estimated $43.3M and bringing the position to 703,043 shares worth $44.2M. The position accounts for 0.26% of the portfolio, ranked #76.

Macquarie Group first reported a position in DXCM in Q2 2013 and has held it in 52 quarters since. The position peaked at $604M in Q4 2021. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Macquarie Group held 703,043 shares of DexCom worth $44.2M as of Q1 2026.
  • Macquarie Group bought 622,459 DexCom shares in Q1 2026, an estimated $43.3M.
  • DexCom made up 0.26% of Macquarie Group's portfolio in Q1 2026, its #76 holding.
  • Macquarie Group first reported a position in DexCom in Q2 2013 and has held it in 52 quarters since.
  • Macquarie Group's DexCom position peaked at $604M in Q4 2021.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Macquarie Group's 13F filing for Q1 2026, filed 15 May 2026.